🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

136+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 20 of 136 recruiting trials for “fibrolamellar-hepatocellular-carcinoma

Phase 1RecruitingNCT06478693

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

👨‍⚕️ Matthew Maurer, MD, Myeloid Therapeutics📍 9 sites📅 Started Jul 2024View details ↗
RecruitingNCT06430983

Recurrent Liver Cancer: Reconceptualization and Reevaluation

👨‍⚕️ zhang yewei, doctor, Nanjing Medical University📍 1 site📅 Started Jul 2024View details ↗
Phase 2RecruitingNCT06397222

Sintilimab Plus Bevacizumab and SIRT for Intermediate-advanced HCC

🏥 Second Affiliated Hospital of Guangzhou Medical University📍 1 site📅 Started May 2024View details ↗
Phase 4RecruitingNCT06311929

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

👨‍⚕️ Xiaoping Chen, Tongji Hospital📍 1 site📅 Started Apr 2024View details ↗
Phase 2, PHASE3RecruitingNCT07293468

Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH)

🏥 Tuen Mun Hospital📍 1 site📅 Started Apr 2024View details ↗
RecruitingNCT06342414

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

👨‍⚕️ Ajay Goel, PhD, City of Hope Medical Center📍 5 sites📅 Started Mar 2024View details ↗
Phase 2RecruitingNCT06261125

Combination of SBRT, PD-L1 Inhibitor, and Lenvatinib in Hepatocellular Carcinoma (HSBRT2401)

👨‍⚕️ Mian Xi, MD, Sun Yat-sen University📍 1 site📅 Started Mar 2024View details ↗
RecruitingNCT06261047

Radiotherapy Delays Second-line Drug Therapy for Oligo Progressive Primary Liver Cancer

👨‍⚕️ jibo yue, dorctor, Shandong Cancer Hospital and Institute📍 1 site📅 Started Mar 2024View details ↗
NARecruitingNCT05911633

BioPearl™ Microspheres Loaded With Doxorubicin for the Treatment of Unresectable Hepatocellular Carcinoma (HCC)

👨‍⚕️ Marie-Pierre Dewez, Terumo Europe EMCD📍 10 sites📅 Started Feb 2024View details ↗
Phase 1, PHASE2RecruitingNCT06027086

DRP-104 (Glutamine Antagonist) in Combination With Durvalumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)

👨‍⚕️ Marina Baretti, MD, SKCCC • Johns Hopkins Medical Institution📍 1 site📅 Started Feb 2024View details ↗
NARecruitingNCT06236568

Impact of Graft Reconditioning With Hypothermic Machine Perfusion on HCC Recurrence After Liver Transplantation

👨‍⚕️ Fabrizio Di Benedetto, University of Modena and Reggio Emilia📍 1 site📅 Started Feb 2024View details ↗
NARecruitingNCT06265350

Cryoablation Combined With Cardonilizumab and Bevacizumab in Hepatocellular Carcinoma With Pulmonary Metastases

👨‍⚕️ Zhimei Hunag, MD, Sun Yat-sen University📍 2 sites📅 Started Feb 2024View details ↗
Phase 2, PHASE3RecruitingNCT06109272

A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as an IV Solution in Adult Participants With Hepatocellular Carcinoma (HCC)

👨‍⚕️ ABBVIE INC., AbbVie📍 37 sites📅 Started Jan 2024View details ↗
Phase 4RecruitingNCT06084234

National Liver Cancer Screening Trial

👨‍⚕️ Amit Singal, MD, MS, University of Texas Southwestern Medical Center📍 18 sites📅 Started Dec 2023View details ↗
NARecruitingNCT06190665

DEB-TACE With Visualable Microspheres Versus PVA Microspheres for HCC

👨‍⚕️ Gao-Jun Teng, Zhongda Hospital📍 2 sites📅 Started Dec 2023View details ↗
RecruitingNCT05705219

Development of 3D Multi-Parametric Ultrasound (MPUS) as a Decision Support Tool for Patients

👨‍⚕️ Ahmed El Kaffas, PhD, University of California, San Diego📍 3 sites📅 Started Dec 2023View details ↗
Phase 2RecruitingNCT06034977

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

👨‍⚕️ Wei-Ting Chen, MD, Chang Gung Memorial Hospital📍 1 site📅 Started Dec 2023View details ↗
RecruitingNCT06117891

An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery

🏥 Bayer📍 20 sites📅 Started Nov 2023View details ↗
Phase 2RecruitingNCT06133062

Atezolizumab and Bevacizumab With Proton Radiotherapy for Unresectable Hepatocellular Carcinoma

🏥 Chang Gung Memorial Hospital📍 1 site📅 Started Nov 2023View details ↗
Enrolling by InvitationNCT05429190

Validation of SMS Protocol for HCC Screening in High-risk Patients

👨‍⚕️ Prof. Dr. de Man, Erasmus Medical Center📍 6 sites📅 Started Nov 2023View details ↗
← PreviousPage 4 of 7Next →

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →